PERSPECTA

News from every angle

← Back to headlines

Apogee Therapeutics Stock Rises on Positive Drug Trial Data

Apogee Therapeutics shares have increased following positive phase 2 clinical trial results for its drug Zumilokibart, intended for atopic dermatitis treatment.

23 Mar, 10:52 — 23 Mar, 10:52
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed165d ago

Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis

Read full article →

Related Stories

Japan and U.S. Advance $550 Billion Investment Pact Focused on AI and Chips

11m ago

Stock Markets Drop Following Strong U.S. Jobs Report

1h ago

Anthropic Delays AI Startup IPO to Mid-October Amid Credit Facility Deal

2h ago

Trade Negotiations Stall as U.S. Halts Antitrust Cooperation With Canada

2h ago